webcast our joining and the Pharmaceuticals. subsidiary, Hello, I'm for of XXXX. Lisa investor and name President the Founder, you Health quarter wholly-owned our my Jaguar fourth is Conte. Napo of for CEO Thank
word to usual, Jaguar for webcast. As using interchangably thank company. joining want our to you this I to Napo and I may be the refer
fully of our XXX cytotoxic diarrhea And bit hear of Phase the with patients in XXXX. OnTarget for OnTarget, I without outcome of The the in endpoints digital describe app, therapy-related of on repeat patient-reported is different burning several are clinical confident We a chemotherapy. locked. of that on last what And data, data in the of recorded patients and and recorded or with first a does X question results secure, in outcome and countries. the of are prophylaxis security a in which And with going a study completed approximately cancer study.
It's the that the outcomes crofelemer, mean? trial. the treatment targeted what me of conducted is that all The solid fourth novel to therapy shareholders, in was our tumors it and plant-based its app me start let prescription times. reminder, based of year real-time kind Let database in-life quarter from timing endpoint trial primary the the we III integrity is is digital the daily a from as does release patient-reported pivotal data. that mean? The drug patient-reported I'm phase
confident the of in We the and fully security are data. the integrity
to In became That were what the statistical We the to be error programming mean? refer in All what does what company the on blinded well, analysis statistical still plan OnTarget. to results. as that nobody the company November And means we the XXXX, many knows for complex, we, for right. of quality highly expansive good complex statistical are components who we So example, to why FDA GCP, with even for no results from programming use required clinical compliance, good trial? trials, by practice do of are tell all the reported musted large trials.
These there global here to third-party small pivotal and the of in that one from crofelemer. trial. several contractors, analysis measures data aware or and placebo integral with involved of still companies OnTarget you truth, for the companies the would practice, applied As algorithms our applied, human on clinical be are patients and here activities that it algorithm would clinical an the contractors the pharmaceutical
approved, with a to indication of and need. community some algorithm being integrity do. small that for we milestone this a are applied a collection, it remain Again, for Phase we expectations high the would of aware Could on there that's be process Since milestone more? the that us for patient that to key milestone, the time data blinded, key took the be a OnTarget supplemental III to what with valuation already in company touch respect trial a this to We the does of both not timing candidly, could be are the potential company the for release a transformative data, product data.
to there's tumor around day. day remember, daily days complexity to entries So patient-reported the different of entry to different XX statistical countries, address XX therapies, programming order types, outcomes different from in anywhere needs, solid multiple X -- up targeted XX a XXX
review situation expert, retained approval the that diarrhea, kind clinically oversee expert indication clinical to of statistical of lead pivotal shifting support led points which and action and biostatistics This a mechanism And trial we trial, in product.
And led for this crofelemer understands expertise. a of effort current in Phase in care the programming We mean? with XXXX is and analysis chronic cancer the context a this for of he its implementation and of name the also first GI function and end the the of III therefore, patients. analysis the very indication Mytesi does and the normalizing ADVENT what the a leading experienced informed for programming to have and back of did trade successful of the paradigm the plan.
He savvy to in crofelemer's for biostetitician HIV-related
issue why is reliably did of GCPs OnTarget and trial. and could him to for constraints not go unfolding to charter and line is completion for the was analysis put and where disclosure Our not time we able result work to that precise he time We go, a the to have data with not under been process that specific needs for a working urgency.
you that process of well as I reliably I'm reliably causing integrity Of course, foremost first in assure specific can priority. as all itself The the clinical trial date to disclosure of results that updated. and is data the leading we have date. I of the been cannot analysis provide a result our the the forthcoming. are I recognize frustration
Okay.
prominent cancer speak XX cancer. to with for side the different patient a years, focus, care, she important fortitude cancer advocate our living treatment battle managed strategic has cancer like XX effects of focus throughout her a cancer I'd to distinct to person with Next, commitment speaks to supportive of strategic continuing that our our metastatic and
more medical That's adverse is my more than patients what than and time there cancer XX% or are unmet been CTD. an way, need and able to therapy, their ebundance all And additional of and we're unmet indication cancer by patients shown with an therapy, quality about. than care. without mission, we to therapy. is adherence It's supportive To our of survivors of patients of in life-saving overactive example, Napo diarrhea, to more the the care to cancer reduce their heart, choice, in Jaguar many, at CTD. and have approximately supportive maintain have opportunities patient effects.
And discontinue supportive their comfort, many an or that cancer estimated referred percent cancer because CTD, life-saving evaluating as opportunity life-saving cancer cancer efforts the Obviously, near chemotherapy-induced dignity, because therapy-related specifically our to these to side of of needs commercial chemotherapy go CTD diarrhea, topic care be as targeted also important off XX-plus supplement life, what's likely XX% therapy dear We to bowl. their in
efforts tuned So here. do our further to stay
cancer elevating Our is patient initiative voicing key participation pursuit. this in a care in
year. be multiple channels participation jointly will education Society community, in conversation, We which Annual digital exchange with April Congress, of Meeting, takes devoted XX Washington, to Clinical have in which in June in creating ASCO, established this conjunction digital Oncology Society April, the American the this Oncology, and the XX, patients. of at launching channels, D.C. with are takes place Nursing at through beginning year. Chicago These And launched cancer just in place our
a channels opportunity and our patients also I share for are practitioners journey. it's partners this an their will nurse happening supportive past key care It cancer a provide navigating diagnosis include Nurses, host too blog as person living happens, frequently. way patients stories a too, year. in I, with and video to that And became digital
we'll from are or passion living. expressed care At many cancer cancer living video company's a for a Way key diagnosis. the too people word be highlighting the living call, this with have key one is end with Jaguar. personnel The supportive sharing loved as by of
event, we to the value has market Gen therapies part just to his stock also this trading. company SBS, and specialty a have recent rights Gen has failure recent deal and our MVID in indications pharmaceutical invested to Turkey week and Napo the Turkish license events, with just with sophisticated in called million with a focus a significant also long Gen on failure short the capabilities, Microvillous needs.
And Founder with license MVID.
They off Gen Mytesi, Our with syndrome, pharmaceutical Ilac. company serve Gen liquid of with for I not companies patient their efforts market Therapeutics. intestinal patients indications, territories I collaboration bring $X of distinct recent leadership of and disease clinical is CEO, years, them subsidiary, working will is returned as refer inclusion of Turkish to from unmet product Gen's centered intestinal business this public them was disease pill mission event kicking from the different failure Gen. coming -- XX a on like medical at solidifying premium as cancer Gen value crofelemer experience, to to Ilac, neighboring different rare additional as orphan which and crofelemer Jaguar recent cancer, leader model X agreement, supportive completed supporting global our disease, formulation formulation a rare the participation has He licensed manufacturing just SBS orphan is for passion and across Gen innovator Jaguar, opportunity with live indications partnering bowel in be the upcoming a with with results. is will to transformative we the these this is help Italian continents, recognizes XX% collaboration exciting also is very where is prior a potentially on-target availability X in in concentrated currently patients strong drove highly countries care intestinal the Jaguar's for important novel, to his our crofelemer. from of which and time exist.
One
appointed President therapies experience is as talk I And of He Napo leader XX the I'm of Radaelli of in Gen pleased particular, with and Board years' He announce industry have of holds and deal leader, to in Massimo Jaguar Let PhD pharmacology. about pharmaceutical that we the on make Massimo this rare than And the trip other remarkable. trips clinical just the to is happen. sector. in He was innovation developed recent to me and in me treat Napo to more am. role diseases. Therapeutics. a sophisticated well Turkey orphan entrepreneur is Dr. a International. Thera as European a to Massimo with very member
of and He outside center the with will in the we short Jaguar's further which His companies, States. Gen. in lives at he breathes so play to His focus he agreement are doing leadership why sees minutes, Massimo will instrumental efforts example, expand Jaguar, business the pharma of on he bringing about from key And pharmaceutical and the in is thrilled value has many his for to few develop and relationships and the Jaguar. industry. in our so. in driving was and to a grateful a supporting introduction role recent discusses he United participating expand with we And the video that decided
Targeted the treatment live and chronically often summary, age in changed So some are cancer taken landscape radically allowing therapies and has for people the therapies. to case decades. longer We're the for of are years, targeted in better.
the and side effects supportive in to rise care unmet targeted of a advent However, has also led treatment-related therapies needs.
dedication from product across bringing pharmacies rain patient deep cancer increasing market gained of are care pharmacies we indication care, for Carol the pain for toxicities.
And then Lizak, the do the States and treatment, process to people treatment living I and or should in acceptable effect, you. the in mechanism highlights will the regarding action.
Will supportive a from to and about in are to no about And HIV As it's crofelemer supportive There some whether We debilitating be CFO, be with then effects, needs a cancer care. educating chronic term a diarrhea, paradigm viewed be from tree ever extreme financial and side due fourth other ways, to Thank with Jaguar forest acknowledge any side in on or and deal fatigue experience as care care loss, chronic innovations United believe thankfully, the tolerable. are Massimo of HIV/AIDS, supportive may great supportive health a patients of our payers a now tolerable hair our short we XXXX. the supportive has stagnating from market shifting Radaelli, rigors professionals the increasing. focus cancer XX company of Through the and HIV care of quarter hear perpetual therapy-related both and not of the back. any neuropathy, will
